The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical drug candidate QLS12004 has obtained tacit clinical trial approval. This marks a significant step forward in the development of new treatments for solid tumors, including advanced breast cancer, which is the leading malignant cancer affecting women’s health worldwide.
QLS12004: Development and Indications
QLS12004 is an in-house developed chemical drug designed to treat solid tumors, with a particular focus on advanced breast cancer. This approval from the CDE paves the way for further clinical development and potential market availability of this innovative treatment.
Pre-Clinical Study Results
Pre-clinical studies conducted both in vivo and in vitro have shown that QLS12004 demonstrated excellent tumor inhibition effects. These results highlight the potential of QLS12004 to significantly improve outcomes for patients with solid tumors, particularly those suffering from advanced breast cancer.-Fineline Info & Tech
